Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10682242 | 0.86 | HTR6 (0.50) | HTR6ALDH1A1CYP3A4MAPK1CA2 | |
| SCHEMBL27609957 | 0.84 | ALDH1A1 (0.46) | HTR6ALDH1A1CA2CA12CA1 | |
| SCHEMBL17212140 | 0.82 | LMNA (0.48) | HTR6ALDH1A1CA2CA12CA1 | |
| SCHEMBL6582653 | 0.82 | CA2 (0.67) | CA2CA12CA1CA4CA6 | |
| SCHEMBL6581495 | 0.82 | ENPP2 (0.46) | ALDH1A1CA2CA12CA1CA4 | |
| SCHEMBL29082923 | 0.82 | ALDH1A1 (0.41) | HTR6ALDH1A1CA2CA12CA1 | |
| SCHEMBL3539406 | 0.80 | CYP3A4 (0.52) | HTR6ALDH1A1CYP3A4MAPK1CA2 | |
| SCHEMBL9860834 | 0.79 | GFER (0.42) | ALDH1A1CA2HTR2AGAAADAM17 | |
| SCHEMBL1939063 | 0.79 | ALDH1A1 (0.41) | HTR6ALDH1A1CA2CA12CA1 | |
| SCHEMBL27387844 | 0.78 | HTR6 (0.55) | HTR6ALDH1A1CYP3A4MAPK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118763273-A | Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof | 青岛赛锂达储能产业技术研究院有限公司 | 2024-10-11 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| CN-118763273-A | Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof | 青岛赛锂达储能产业技术研究院有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-105175397-A | Synthesis method of eletriptan hydrobromate | SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD | 2015-12-23 | — | — | CN | disclosed |
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | disclosed |
| US-8115046-B2 | Micro encapsulation composition for hydrocarbons and detoxification of highly hazardous chemicals and substances | RTA SYSTEMS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| CN-101142180-B | Pyrrolidine derivatives as histamine h3 receptor antagonists | LILLY CO ELI | 2011-05-04 | — | — | CN | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| US-4895840-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0295010-A1 | Derivatives of alkylaminoalkyl ureas and cyanoguanidines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-12-14 | — | — | EP | disclosed |
| US-4724235-A | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-09 | — | — | US | disclosed |
| US-4597902-A | TREATMENT OF CARDIAC ARRHYTHMIAS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0066415-B1 | N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0066415-A2 | N-(arylthioalkyl)-N'-(aminoalkyl)ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | HTR3C, SLC6A4, HTR3A | HTR6 28/4885ALDH1A1 2989/4885CYP3A4 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.